Brokerages Set AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target at $20.38

Shares of AbCellera Biologics Inc. (NASDAQ:ABCL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month […]

Related Keywords

Piper Sandler ,Eli Lilly ,Abcellera Biologics ,Nasdaq ,Abcellera Biologics Company Profile ,Keycorp ,Belpointe Asset Management ,Piper Sandler Companies ,Pricet Rowe Associates Inc ,Stansberry Asset Management ,Pathstone Family Office ,Pacifica Partners Inc ,Abcellera Biologics Inc ,Get Free Report ,Sandler Companies ,Cellera Biologics ,Asset Management ,Family Office ,Get Free ,Cellera Biologics Inc ,Confo Therapeutics ,Abcellera Biologics Daily ,Nasdaq Abcl ,Abcl ,Medical ,Ratings ,Consensus ,